Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H14Cl2O3 |
| Molecular Weight | 325.187 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(OC1=CC=C(Cl)C=C1)C(=O)OC2=CC=C(Cl)C=C2
InChI
InChIKey=NIVDRJXCJCEFDD-UHFFFAOYSA-N
InChI=1S/C16H14Cl2O3/c1-16(2,21-14-9-5-12(18)6-10-14)15(19)20-13-7-3-11(17)4-8-13/h3-10H,1-2H3
| Molecular Formula | C16H14Cl2O3 |
| Molecular Weight | 325.187 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Dulofibrate is a fibrate derivative with antilipidemic activity. Unlike clofibrate, dulofibrate is selective for a reduction in triglycerides. Dulofibrate decreased the conjugation of nopol. Dulofibrate exhibited a clofibrate-like effect on the induction of hepatic drug-metabolizing enzymes, characterized by an increase in lauric acid 12-hydroxylation and bilirubin UDP-glucuronosyltransferase activities. Dulofibrate and fenofibrate have been shown to possess an equal potency as peroxisome proliferators.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2885979
Curator's Comment: Rat data
200 mg/kg per day once a day for five days
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:33:18 GMT 2025
by
admin
on
Mon Mar 31 18:33:18 GMT 2025
|
| Record UNII |
5K0215OMQX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C98150
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB06423MIG
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
4776
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
68812
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
DTXSID10866891
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
100000081012
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
61887-16-9
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL2106328
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
C041053
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
5K0215OMQX
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY | |||
|
C65494
Created by
admin on Mon Mar 31 18:33:18 GMT 2025 , Edited by admin on Mon Mar 31 18:33:18 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |